Becton Dickinson & Co stock (US0758871091): Norges Bank stake highlights interest after recent earnings beat

Becton Dickinson & Co shares on the NYSE traded around the mid-140 USD range on 06/01/2026, as fresh filings showed Norway's Norges Bank building a sizeable position in the U.S. medical technology group following a quarterly earnings beat in early May.

Becton Dickinson & Co shares were changing hands in the mid-140 USD area on the New York Stock Exchange on 06/01/2026, with the U.S. medical technology stock in focus after a recent filing showed that Norway's central bank, Norges Bank, accumulated a multi-billion dollar stake following the company's latest earnings release, according to MarketBeat data as of 06/01/2026.

The filing indicated that Norges Bank acquired about 3,783,792 Becton Dickinson & Co shares valued at roughly USD 734.3 million, signaling continued institutional interest in the Franklin Lakes, New Jersey-based group that is part of the U.S. health care sector.

On 05/02/2026 Becton Dickinson & Co reported quarterly earnings per share of USD 2.90 versus a consensus estimate of USD 2.77, while revenue for the quarter reached USD 4.71 billion compared with analyst expectations of USD 4.67 billion, according to MarketBeat as of 06/01/2026.

The stock recently traded near USD 147 on U.S. markets, with intraday levels that day including a high just above USD 149 and a low around USD 145, based on real-time price data collated by Moneycontrol as of 06/01/2026.

The shares remain actively listed in the United States on the NYSE under the ticker BDX, with no completed take-private or delisting transaction reported in recent regulatory or exchange filings as of 06/01/2026.

For German investors, Becton Dickinson & Co is also accessible on alternative trading venues such as Tradegate in euro, typically mirroring the underlying NYSE price with currency adjustments, though liquidity and spreads can differ from the home market.

In the fixed-income and dividend context, Becton Dickinson & Co has historically been recognized as a reliable payer and is often cited among U.S. companies with long-term dividend growth track records, as highlighted in a 2024 feature on dividend champions by Investing.com.

The acquisition by Norges Bank adds to the broader pool of institutional investors that use the stock for exposure to global medical devices and diagnostics, and it comes shortly after the company delivered better-than-expected top-line and bottom-line figures for its latest reported quarter.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: BDX
• Sector/industry: Medical technology and diagnostics
• Headquarters/country: Franklin Lakes, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Medical delivery systems, diagnostic solutions, interventional products
• Home exchange/listing venue: NYSE (BDX)
• Trading currency: USD

Becton Dickinson & Co: core business model

Becton Dickinson & Co focuses on designing and supplying medical devices, diagnostic equipment, and interventional products that support hospitals, laboratories, and healthcare providers worldwide.

What banks and research houses say about Becton Dickinson & Co

According to consensus data compiled by MarketBeat as of 06/01/2026, analyst coverage on Becton Dickinson & Co currently points to an average rating of "Hold" with a mean price target of about USD 183.64 per share, based on their aggregation of published research.

This consensus snapshot suggests that, while views on the stock are mixed, the average target level sits well above the stock's mid-140 USD trading range seen on 06/01/2026 on the NYSE, highlighting a gap between recent market pricing and the longer-term expectations embedded in sell-side models.

Conclusion

The combination of a sizeable Norges Bank stake and a recent quarterly earnings beat has put Becton Dickinson & Co back into focus on its U.S. home market, where the stock trades on the NYSE around the mid-140 USD range as of 06/01/2026.

Consensus data compiled by MarketBeat indicates that analysts overall lean toward a Hold stance with an average price target above the current share price, underlining how institutional capital and sell-side expectations intersect around the company's long-term role in global medical technology.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.